PCIDB

KNApSAcK Metabolite C00041217

Metabolite

KNApSAcK Entry

id C00041217
Name Vitamin D3 / Cholecalciferol
CAS RN 67-97-0
Standard InChI InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
Standard InChI (Main Layer) InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3

Cluster

Phytochemical cluster
KCF-S cluster No. 4779

Link

ChEMBL

By standard InChI CHEMBL1042
By standard InChI Main Layer CHEMBL1042 CHEMBL432780 CHEMBL1236645 CHEMBL1354424 CHEMBL1365250 CHEMBL1456744 CHEMBL1475972 CHEMBL1949934 CHEMBL1966661

KEGG

By LinkDB C05443

CTD

By CAS RN D002762

Human Protein / Gene in interaction

117 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P10635 Cytochrome P450 2D6 Cytochrome P450 2D6 CHEMBL1042 CHEMBL1475972 CHEMBL1741321 (1) CHEMBL1909136 (2)
1 / 0
P22310 UDP-glucuronosyltransferase 1-4 Enzyme CHEMBL1042 CHEMBL1908082 (1)
3 / 0
P04637 Cellular tumor antigen p53 Transcription Factor CHEMBL1042 CHEMBL2114895 (1)
7 / 44
Q16637 Survival motor neuron protein Unclassified protein CHEMBL1042 CHEMBL1613842 (1)
4 / 2
P21728 D(1A) dopamine receptor Dopamine receptor CHEMBL1042 CHEMBL1909139 (2)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL1042 CHEMBL1909131 (2)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL1042 CHEMBL1909190 (2)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL1042 CHEMBL1909195 (2)
2 / 1
P33765 Adenosine receptor A3 Adenosine receptor CHEMBL1042 CHEMBL1909215 (2)
0 / 0
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL1042 CHEMBL1909201 (2)
0 / 0
P49146 Neuropeptide Y receptor type 2 Neuropeptide Y receptor CHEMBL1042 CHEMBL1909176 (2)
0 / 0
P29466 Caspase-1 C14 CHEMBL1042 CHEMBL1909193 (2)
0 / 0
P17252 Protein kinase C alpha type Alpha CHEMBL1042 CHEMBL1909198 (2)
0 / 0
P27361 Mitogen-activated protein kinase 3 Erk CHEMBL1042 CHEMBL1909199 (2)
0 / 0
Q03181 Peroxisome proliferator-activated receptor delta NR1C2 CHEMBL1042 CHEMBL1794524 (1) CHEMBL1794552 (1)
0 / 0
P14780 Matrix metalloproteinase-9 M10A CHEMBL1042 CHEMBL1909197 (2)
2 / 2
P10828 Thyroid hormone receptor beta NR1A2 CHEMBL1042 CHEMBL1794399 (1)
3 / 1
P19793 Retinoic acid receptor RXR-alpha NR2B1 CHEMBL1042 CHEMBL1794371 (1)
0 / 0
P00918 Carbonic anhydrase 2 Lyase CHEMBL1042 CHEMBL1909123 (2)
1 / 2
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL1042 CHEMBL1909092 (2)
0 / 1
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL1042 CHEMBL1909169 (2)
1 / 1
P25021 Histamine H2 receptor Histamine receptor CHEMBL1042 CHEMBL1909157 (2)
0 / 0
P35367 Histamine H1 receptor Histamine receptor CHEMBL1042 CHEMBL1909156 (2)
0 / 0
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL1042 CHEMBL1909143 (2)
1 / 0
P08912 Muscarinic acetylcholine receptor M5 Acetylcholine receptor CHEMBL1042 CHEMBL1909174 (2)
0 / 0
P18825 Alpha-2C adrenergic receptor Adrenergic receptor CHEMBL1042 CHEMBL1909090 (2)
0 / 0
P13945 Beta-3 adrenergic receptor Adrenergic receptor CHEMBL1042 CHEMBL1909093 (2)
0 / 0
P25024 C-X-C chemokine receptor type 1 CXC chemokine receptor CHEMBL1042 CHEMBL1909127 (2)
0 / 0
P06241 Tyrosine-protein kinase Fyn Src CHEMBL1042 CHEMBL1909204 (2)
0 / 0
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Ser_Thr CHEMBL1042 CHEMBL1909202 (2)
0 / 0
P11712 Cytochrome P450 2C9 Cytochrome P450 2C9 CHEMBL1042 CHEMBL1475972 CHEMBL1741325 (1) CHEMBL1909135 (2)
0 / 1
P00533 Epidermal growth factor receptor TK tyrosine-protein kinase EGFR subfamily CHEMBL1042 CHEMBL1909203 (2)
1 / 11
P11473 Vitamin D3 receptor NR1I1 CHEMBL1042 CHEMBL1236645 CHEMBL1949934 CHEMBL1794311 (2) CHEMBL1794376 (1)
CHEMBL1794339 (1) CHEMBL1953623 (2)
CHEMBL1953630 (2) CHEMBL1953631 (2)
CHEMBL2066209 (2) CHEMBL2066210 (2)
2 / 3
P14416 D(2) dopamine receptor Dopamine receptor CHEMBL1042 CHEMBL1909140 (2)
2 / 0
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL1042 CHEMBL1909130 (2)
0 / 0
P37288 Vasopressin V1a receptor Vasopressin and oxytocin receptor CHEMBL1042 CHEMBL1909120 (2)
0 / 0
P41145 Kappa-type opioid receptor Opioid receptor CHEMBL1042 CHEMBL1909181 (2)
0 / 0
Q9Y271 Cysteinyl leukotriene receptor 1 Leukotriene receptor CHEMBL1042 CHEMBL1909164 (2)
0 / 0
P29274 Adenosine receptor A2a Adenosine receptor CHEMBL1042 CHEMBL1909214 (2)
0 / 0
P25929 Neuropeptide Y receptor type 1 Neuropeptide Y receptor CHEMBL1042 CHEMBL1909175 (2)
0 / 0
P50052 Type-2 angiotensin II receptor Angiotensin receptor CHEMBL1042 CHEMBL1909096 (2)
1 / 1
P17948 Vascular endothelial growth factor receptor 1 Vegfr CHEMBL1042 CHEMBL1909118 (2)
0 / 0
P41968 Melanocortin receptor 3 Melanocortin receptor CHEMBL1042 CHEMBL1909166 (2)
1 / 0
P00352 Retinal dehydrogenase 1 Enzyme CHEMBL1042 CHEMBL1354424 CHEMBL1614458 (3)
0 / 0
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL1042 CHEMBL1909133 (2)
0 / 0
O75496 Geminin Unclassified protein CHEMBL1042 CHEMBL2114843 (1)
0 / 0
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oxidoreductase CHEMBL1042 CHEMBL1909158 (2)
0 / 0
P08913 Alpha-2A adrenergic receptor Adrenergic receptor CHEMBL1042 CHEMBL1909088 (2)
0 / 0
P21917 D(4) dopamine receptor Dopamine receptor CHEMBL1042 CHEMBL1909142 (2)
0 / 0
P30988 Calcitonin receptor Calcitonin receptor CHEMBL1042 CHEMBL1909101 (2)
0 / 0
P35462 D(3) dopamine receptor Dopamine receptor CHEMBL1042 CHEMBL1909141 (2)
1 / 0
P41143 Delta-type opioid receptor Opioid receptor CHEMBL1042 CHEMBL1909180 (2)
0 / 0
Q92731 Estrogen receptor beta NR3A2 CHEMBL1042 CHEMBL1909146 (2)
0 / 1
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL1042 CHEMBL1909104 (2)
0 / 0
P25101 Endothelin-1 receptor Endothelin receptor CHEMBL1042 CHEMBL1909144 (2)
0 / 0
P30411 B2 bradykinin receptor Bradykinin receptor CHEMBL1042 CHEMBL1909100 (2)
0 / 0
P10145 Interleukin-8 Secreted protein CHEMBL1042 CHEMBL2114835 (1)
0 / 0
P32245 Melanocortin receptor 4 Melanocortin receptor CHEMBL1042 CHEMBL1909167 (2)
1 / 0
P32238 Cholecystokinin receptor type A Cholecystokinin receptor CHEMBL1042 CHEMBL1909129 (2)
0 / 0
P08311 Cathepsin G S1A CHEMBL1042 CHEMBL1909194 (2)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL1042 CHEMBL1909110 (2)
1 / 0
P03956 Interstitial collagenase M10A CHEMBL1042 CHEMBL1909196 (2)
0 / 1
P32241 Vasoactive intestinal polypeptide receptor 1 Vasoactive intestinal peptide receptor CHEMBL1042 CHEMBL1909119 (2)
0 / 0
O94782 Ubiquitin carboxyl-terminal hydrolase 1 Enzyme CHEMBL1042 CHEMBL1475972 CHEMBL1794467 (2)
0 / 0
P04150 Glucocorticoid receptor NR3C1 CHEMBL1042 CHEMBL1794382 (1) CHEMBL1909150 (2)
0 / 1
P08172 Muscarinic acetylcholine receptor M2 Acetylcholine receptor CHEMBL1042 CHEMBL1909171 (2)
2 / 0
P11229 Muscarinic acetylcholine receptor M1 Acetylcholine receptor CHEMBL1042 CHEMBL1909170 (2)
0 / 0
P21554 Cannabinoid receptor 1 Cannabinoid receptor CHEMBL1042 CHEMBL1909122 (2)
0 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL1042 CHEMBL1909109 (2)
2 / 0
P37231 Peroxisome proliferator-activated receptor gamma NR1C3 CHEMBL1042 CHEMBL1794510 (1)
5 / 3
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL1042 CHEMBL1909205 (2)
5 / 10
P20309 Muscarinic acetylcholine receptor M3 Acetylcholine receptor CHEMBL1042 CHEMBL1909172 (2)
1 / 0
P21452 Substance-K receptor Neurokinin receptor CHEMBL1042 CHEMBL1909114 (2)
0 / 0
P30304 M-phase inducer phosphatase 1 Ser_Thr_Tyr CHEMBL432780 CHEMBL662885 (1)
0 / 0
P51679 C-C chemokine receptor type 4 CC chemokine receptor CHEMBL1042 CHEMBL1909125 (2)
0 / 0
P51681 C-C chemokine receptor type 5 CC chemokine receptor CHEMBL1042 CHEMBL1909126 (2)
3 / 0
P50406 5-hydroxytryptamine receptor 6 Serotonin receptor CHEMBL1042 CHEMBL1909108 (2)
0 / 0
Q96RI1 Bile acid receptor NR1H4 CHEMBL1042 CHEMBL1794415 (1) CHEMBL1794437 (1)
0 / 0
P41597 C-C chemokine receptor type 2 CC chemokine receptor CHEMBL1042 CHEMBL1909124 (2)
1 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL1042 CHEMBL1909200 (2)
0 / 0
P08575 Receptor-type tyrosine-protein phosphatase C Enzyme CHEMBL1042 CHEMBL1909207 (2)
2 / 1
P05177 Cytochrome P450 1A2 Cytochrome P450 1A2 CHEMBL1042 CHEMBL1475972 CHEMBL1741322 (1) CHEMBL1909132 (2)
0 / 0
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 Enzyme CHEMBL1042 CHEMBL1614227 (1)
3 / 3
P15428 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Enzyme CHEMBL1042 CHEMBL1614038 (1)
2 / 2
P51449 Nuclear receptor ROR-gamma Nuclear hormone receptor subfamily 1 group F member 3 CHEMBL1042 CHEMBL2114842 (1)
0 / 0
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase PDE_5A CHEMBL1042 CHEMBL1909186 (2)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL1042 CHEMBL999944 (1) CHEMBL1794364 (1)
CHEMBL1794542 (1) CHEMBL1909145 (2)
1 / 1
P08588 Beta-1 adrenergic receptor Adrenergic receptor CHEMBL1042 CHEMBL1909091 (2)
1 / 0
P22303 Acetylcholinesterase Hydrolase CHEMBL1042 CHEMBL1909212 (2)
1 / 0
P28223 5-hydroxytryptamine receptor 2A Serotonin receptor CHEMBL1042 CHEMBL1909211 (2)
0 / 0
P28335 5-hydroxytryptamine receptor 2C Serotonin receptor CHEMBL1042 CHEMBL1909105 (2)
0 / 0
P35372 Mu-type opioid receptor Opioid receptor CHEMBL1042 CHEMBL1909182 (2)
0 / 0
P08173 Muscarinic acetylcholine receptor M4 Acetylcholine receptor CHEMBL1042 CHEMBL1909173 (2)
0 / 0
P25103 Substance-P receptor Neurokinin receptor CHEMBL1042 CHEMBL1909113 (2)
0 / 0
P25105 Platelet-activating factor receptor PAF receptor CHEMBL1042 CHEMBL1909187 (2)
0 / 0
P33032 Melanocortin receptor 5 Melanocortin receptor CHEMBL1042 CHEMBL1909168 (2)
0 / 0
P16050 Arachidonate 15-lipoxygenase Enzyme CHEMBL1042 CHEMBL1354424 CHEMBL1614240 (2)
0 / 0
P33261 Cytochrome P450 2C19 Cytochrome P450 2C19 CHEMBL1042 CHEMBL1475972 CHEMBL1741323 (1) CHEMBL1909134 (2)
1 / 1
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL1042 CHEMBL1354424 CHEMBL1475972 CHEMBL1614108 (2) CHEMBL1613886 (2)
CHEMBL1741324 (1) CHEMBL1909138 (2)
0 / 1
P05181 Cytochrome P450 2E1 Cytochrome P450 2E1 CHEMBL1042 CHEMBL1909137 (2)
0 / 0
P22309 UDP-glucuronosyltransferase 1-1 Enzyme CHEMBL1042 CHEMBL1908080 (1)
5 / 1
P10636 Microtubule-associated protein tau Unclassified protein CHEMBL1042 CHEMBL1354424 CHEMBL1614250 (1) CHEMBL1614421 (2)
4 / 3
Q16236 Nuclear factor erythroid 2-related factor 2 Unclassified protein CHEMBL1042 CHEMBL2114890 (1)
0 / 0
P10275 Androgen receptor NR3C4 CHEMBL1042 CHEMBL1794560 (1)
3 / 4
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL1042 CHEMBL1909094 (2)
1 / 1
P25100 Alpha-1D adrenergic receptor Adrenergic receptor CHEMBL1042 CHEMBL1909087 (2)
0 / 0
P30542 Adenosine receptor A1 Adenosine receptor CHEMBL1042 CHEMBL1909213 (2)
0 / 0
P18089 Alpha-2B adrenergic receptor Adrenergic receptor CHEMBL1042 CHEMBL1909089 (2)
0 / 0
P24557 Thromboxane-A synthase Cytochrome P450 5A1 CHEMBL1042 CHEMBL1909116 (2)
1 / 1
P06239 Tyrosine-protein kinase Lck Src CHEMBL1042 CHEMBL1909206 (2)
0 / 1
P25025 C-X-C chemokine receptor type 2 CXC chemokine receptor CHEMBL1042 CHEMBL1909128 (2)
0 / 0
Q9UBT6 DNA polymerase kappa Enzyme CHEMBL1042 CHEMBL1354424 CHEMBL1794536 (2)
0 / 0
Q99835 Smoothened homolog Smoothened receptor (frizzled family GPCR) CHEMBL1042 CHEMBL1236645 CHEMBL2066208 (2)
0 / 1
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 Enzyme CHEMBL1042 CHEMBL1738442 (2)
0 / 0
Q9NUW8 Tyrosyl-DNA phosphodiesterase 1 Enzyme CHEMBL1475972 CHEMBL1614364 (1)
1 / 1
O00255 Menin Unclassified protein CHEMBL1354424 CHEMBL1365250 CHEMBL1475972 CHEMBL1614257 (2) CHEMBL1614531 (1)
2 / 5
Q03164 Histone-lysine N-methyltransferase 2A Enzyme CHEMBL1354424 CHEMBL1365250 CHEMBL1475972 CHEMBL1614257 (2) CHEMBL1614531 (1)
1 / 3

CTD interaction (97)

compound gene gene name gene description interaction interaction type form reference
pmid
D002762 10257 ABCC4
EST170205
MOAT-B
MOATB
MRP4
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Cholecalciferol results in decreased expression of ABCC4 mRNA decreases expression
mRNA 19142964
D002762 572 BAD
BBC2
BCL2L8
BCL2-associated agonist of cell death Cholecalciferol results in increased phosphorylation of BAD protein increases phosphorylation
protein 18628207
D002762 572 BAD
BBC2
BCL2L8
BCL2-associated agonist of cell death [Cholecalciferol results in increased phosphorylation of BAD protein] inhibits the reaction [BAD protein binds to BCL2L1 protein] affects binding
/ decreases reaction
/ increases phosphorylation
protein 18628207
D002762 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 Cholecalciferol results in increased expression of BCL2 protein increases expression
protein 18628207
D002762 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]] affects binding
/ decreases reaction
/ increases reaction
protein 18628207
D002762 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 BECN1 mutant form inhibits the reaction [Cholecalciferol results in increased expression of BCL2L1 protein] decreases reaction
/ increases expression
protein 18628207
D002762 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein] affects binding
/ increases reaction
protein 18628207
D002762 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 Cholecalciferol results in increased expression of BCL2L1 protein increases expression
protein 18628207
D002762 598 BCL2L1
BCL-XL/S
BCL2L
BCLX
BCLXL
BCLXS
Bcl-X
PPP1R52
bcl-xL
bcl-xS
BCL2-like 1 [Cholecalciferol results in increased phosphorylation of BAD protein] inhibits the reaction [BAD protein binds to BCL2L1 protein] affects binding
/ decreases reaction
/ increases phosphorylation
protein 18628207
D002762 8678 BECN1
ATG6
VPS30
beclin1
beclin 1, autophagy related ABT-737 inhibits the reaction [Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein]] affects binding
/ decreases reaction
/ increases reaction
protein 18628207
D002762 8678 BECN1
ATG6
VPS30
beclin1
beclin 1, autophagy related BECN1 mutant form inhibits the reaction [Cholecalciferol promotes the reaction [PIK3C3 protein binds to BECN1 protein]] affects binding
/ decreases reaction
/ increases reaction
mutant form / protein 18628207
D002762 8678 BECN1
ATG6
VPS30
beclin1
beclin 1, autophagy related BECN1 mutant form inhibits the reaction [Cholecalciferol results in increased expression of BCL2L1 protein] decreases reaction
/ increases expression
mutant form 18628207
D002762 8678 BECN1
ATG6
VPS30
beclin1
beclin 1, autophagy related Cholecalciferol promotes the reaction [BECN1 protein binds to BCL2L1 protein] affects binding
/ increases reaction
protein 18628207
D002762 8678 BECN1
ATG6
VPS30
beclin1
beclin 1, autophagy related Cholecalciferol promotes the reaction [PIK3C3 protein binds to BECN1 protein] affects binding
/ increases reaction
protein 18628207
D002762 8678 BECN1
ATG6
VPS30
beclin1
beclin 1, autophagy related Cholecalciferol results in increased expression of BECN1 protein increases expression
protein 18628207
D002762 8678 BECN1
ATG6
VPS30
beclin1
beclin 1, autophagy related MTOR mutant form promotes the reaction [Cholecalciferol results in increased expression of BECN1 protein] increases expression
/ increases reaction
protein 18628207
D002762 8678 BECN1
ATG6
VPS30
beclin1
beclin 1, autophagy related PIK3C3 mutant form inhibits the reaction [Cholecalciferol promotes the reaction [PIK3C3 protein binds to BECN1 protein]] affects binding
/ decreases reaction
/ increases reaction
protein 18628207
D002762 632 BGLAP
BGP
OC
OCN
bone gamma-carboxyglutamate (gla) protein [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of BGLAP protein affects cotreatment
/ increases expression
protein 17692823
D002762 632 BGLAP
BGP
OC
OCN
bone gamma-carboxyglutamate (gla) protein Cholecalciferol results in increased secretion of BGLAP protein increases secretion
protein 17996099
D002762 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Cholecalciferol results in decreased expression of CASP9 protein decreases expression
protein 18628207
D002762 898 CCNE1
CCNE
cyclin E1 Cholecalciferol results in decreased expression of CCNE1 protein decreases expression
protein 12907249
D002762 929 CD14
CD14 molecule [Cholecalciferol co-treated with TGFB1 protein] results in increased expression of CD14 mRNA affects cotreatment
/ increases expression
mRNA 15988048
D002762 929 CD14
CD14 molecule Cholecalciferol results in increased expression of CD14 protein increases expression
protein 18628207
D002762 929 CD14
CD14 molecule PML protein mutant form inhibits the reaction [[Cholecalciferol co-treated with TGFB1 protein] results in increased expression of CD14 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15988048
D002762 929 CD14
CD14 molecule RAF1 mutant form inhibits the reaction [Cholecalciferol results in increased expression of CD14 protein] decreases reaction
/ increases expression
protein 18628207
D002762 929 CD14
CD14 molecule RARA protein mutant form inhibits the reaction [[Cholecalciferol co-treated with TGFB1 protein] results in increased expression of CD14 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15988048
D002762 978 CDA
CDD
cytidine deaminase (EC:3.5.4.5) Cholecalciferol results in increased expression of CDA mRNA increases expression
mRNA 18537153
D002762 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) Cholecalciferol promotes the reaction [CDKN1B protein binds to CDK2 protein] affects binding
/ increases reaction
protein 12907249
D002762 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) Cholecalciferol results in decreased activity of CDK2 protein decreases activity
protein 12907249
D002762 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) Cholecalciferol results in decreased phosphorylation of CDK2 protein decreases phosphorylation
protein 12907249
D002762 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Cholecalciferol results in decreased expression of CDKN1A protein decreases expression
protein 12907249
D002762 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) Cholecalciferol promotes the reaction [CDKN1B protein binds to CDK2 protein] affects binding
/ increases reaction
protein 12907249
D002762 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) Cholecalciferol results in increased expression of and results in decreased degradation of CDKN1B protein decreases degradation
/ increases expression
protein 12907249
D002762 1027 CDKN1B
CDKN4
KIP1
MEN1B
MEN4
P27KIP1
cyclin-dependent kinase inhibitor 1B (p27, Kip1) Cholecalciferol results in increased expression of CDKN1B mRNA increases expression
mRNA 12907249
D002762 1032 CDKN2D
INK4D
p19
p19-INK4D
cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) Cholecalciferol results in increased expression of CDKN2D increases expression
16582618
D002762 1591 CYP24A1
CP24
CYP24
HCAI
P450-CC24
cytochrome P450, family 24, subfamily A, polypeptide 1 (EC:1.14.13.126) Cholecalciferol results in increased expression of CYP24A1 mRNA increases expression
mRNA 16207822
D002762 1555 CYP2B6
CPB6
CYP2B
CYP2B7
CYP2B7P
CYPIIB6
EFVM
IIB1
P450
cytochrome P450, family 2, subfamily B, polypeptide 6 (EC:1.14.14.1) Cholecalciferol metabolite results in increased expression of CYP2B6 increases expression
11991950
D002762 1559 CYP2C9
CPC9
CYP2C
CYP2C10
CYPIIC9
P450IIC9
cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) Cholecalciferol metabolite results in increased expression of CYP2C9 increases expression
11991950
D002762 1559 CYP2C9
CPC9
CYP2C
CYP2C10
CYPIIC9
P450IIC9
cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) Cholecalciferol results in decreased activity of CYP2C9 protein decreases activity
protein 18420780
D002762 1565 CYP2D6
CPD6
CYP2D
CYP2D7AP
CYP2D7BP
CYP2D7P2
CYP2D8P2
CYP2DL1
CYPIID6
P450-DB1
P450C2D
P450DB1
cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) Cholecalciferol results in decreased activity of CYP2D6 protein decreases activity
protein 18420780
D002762 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Cholecalciferol metabolite results in increased expression of CYP3A4 increases expression
11991950
D002762 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Cholecalciferol results in decreased activity of CYP3A4 protein decreases activity
protein 18420780
D002762 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Cholecalciferol results in increased expression of CYP3A4 mRNA increases expression
mRNA 16207822
D002762 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) CYP3A4 protein results in increased hydroxylation of Cholecalciferol increases hydroxylation
protein 16207822
D002762 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Cholecalciferol] decreases reaction
/ increases hydroxylation
protein 16207822
D002762 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Phenytoin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Cholecalciferol] increases hydroxylation
/ increases reaction
protein 16207822
D002762 1576 CYP3A4
CP33
CP34
CYP3A
CYP3A3
CYPIIIA3
CYPIIIA4
HLP
NF-25
P450C3
P450PCN1
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) Troleandomycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Cholecalciferol] decreases reaction
/ increases hydroxylation
protein 16207822
D002762 1577 CYP3A5
CP35
CYPIIIA5
P450PCN3
PCN3
cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) CYP3A5 protein results in increased hydroxylation of Cholecalciferol increases hydroxylation
protein 16207822
D002762 3458 IFNG
IFG
IFI
interferon, gamma Cholecalciferol inhibits the reaction [nickel sulfate results in increased secretion of IFNG protein] decreases reaction
/ increases secretion
protein 15663561
D002762 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 Cholecalciferol promotes the reaction [rosiglitazone results in increased expression of IL10 protein] increases expression
/ increases reaction
protein 17822917
D002762 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 Cholecalciferol results in increased expression of IL10 protein increases expression
protein 17822917
D002762 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) Cholecalciferol results in increased expression of IL6 protein increases expression
protein 21050239
D002762 3684 ITGAM
CD11B
CR3A
MAC-1
MAC1A
MO1A
SLEB6
integrin, alpha M (complement component 3 receptor 3 subunit) [Cholecalciferol co-treated with TGFB1 protein] results in increased expression of ITGAM mRNA affects cotreatment
/ increases expression
mRNA 15988048
D002762 3687 ITGAX
CD11C
SLEB6
integrin, alpha X (complement component 3 receptor 4 subunit) [Cholecalciferol co-treated with TGFB1 protein] results in increased expression of ITGAX mRNA affects cotreatment
/ increases expression
mRNA 15988048
D002762 4313 MMP2
CLG4
CLG4A
MMP-II
MONA
TBE-1
matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) (EC:3.4.24.24) Cholecalciferol promotes the reaction [Fenretinide results in decreased activity of MMP2 protein] decreases activity
/ increases reaction
protein 17024972
D002762 4313 MMP2
CLG4
CLG4A
MMP-II
MONA
TBE-1
matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) (EC:3.4.24.24) Cholecalciferol results in decreased activity of MMP2 protein decreases activity
protein 17024972
D002762 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Cholecalciferol results in decreased expression of MTOR decreases expression
18628207
D002762 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) MTOR mutant form promotes the reaction [Cholecalciferol results in increased expression of BECN1 protein] increases expression
/ increases reaction
mutant form 18628207
D002762 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) MTOR results in decreased susceptibility to Cholecalciferol decreases response to substance
18628207
D002762 4538 ND4
MTND4
MT-ND4
NADH dehydrogenase, subunit 4 (complex I) Cholecalciferol results in decreased expression of ND4 mRNA decreases expression
mRNA 10491287
D002762 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Cholecalciferol affects the expression of PARP1 protein affects expression
protein 18628207
D002762 5289 PIK3C3
VPS34
hVps34
phosphatidylinositol 3-kinase, catalytic subunit type 3 (EC:2.7.1.137) BECN1 mutant form inhibits the reaction [Cholecalciferol promotes the reaction [PIK3C3 protein binds to BECN1 protein]] affects binding
/ decreases reaction
/ increases reaction
protein 18628207
D002762 5289 PIK3C3
VPS34
hVps34
phosphatidylinositol 3-kinase, catalytic subunit type 3 (EC:2.7.1.137) Cholecalciferol promotes the reaction [PIK3C3 protein binds to BECN1 protein] affects binding
/ increases reaction
protein 18628207
D002762 5289 PIK3C3
VPS34
hVps34
phosphatidylinositol 3-kinase, catalytic subunit type 3 (EC:2.7.1.137) Cholecalciferol results in increased expression of PIK3C3 protein increases expression
protein 18628207
D002762 5289 PIK3C3
VPS34
hVps34
phosphatidylinositol 3-kinase, catalytic subunit type 3 (EC:2.7.1.137) PIK3C3 mutant form inhibits the reaction [Cholecalciferol promotes the reaction [PIK3C3 protein binds to BECN1 protein]] affects binding
/ decreases reaction
/ increases reaction
mutant form / protein 18628207
D002762 5371 PML
MYL
PP8675
RNF71
TRIM19
promyelocytic leukemia PML protein mutant form inhibits the reaction [[Cholecalciferol co-treated with TGFB1 protein] results in increased expression of CD14 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
protein 15988048
D002762 5741 PTH
PTH1
parathyroid hormone [Cholecalciferol co-treated with Calcium] results in decreased expression of PTH protein affects cotreatment
/ decreases expression
protein 80633
D002762 5741 PTH
PTH1
parathyroid hormone Cholecalciferol results in decreased expression of PTH protein decreases expression
protein 8711172
D002762 5829 PXN
paxillin Cholecalciferol results in increased expression of PXN increases expression
9081214
D002762 5894 RAF1
CRAF
NS5
Raf-1
c-Raf
v-raf-1 murine leukemia viral oncogene homolog 1 (EC:2.7.11.1) RAF1 mutant form inhibits the reaction [Cholecalciferol results in increased expression of CD14 protein] decreases reaction
/ increases expression
mutant form 18628207
D002762 5894 RAF1
CRAF
NS5
Raf-1
c-Raf
v-raf-1 murine leukemia viral oncogene homolog 1 (EC:2.7.11.1) RAF1 mutant form inhibits the reaction [Cholecalciferol results in increased expression of RB1 protein] decreases reaction
/ increases expression
mutant form 18628207
D002762 5894 RAF1
CRAF
NS5
Raf-1
c-Raf
v-raf-1 murine leukemia viral oncogene homolog 1 (EC:2.7.11.1) RAF1 results in increased susceptibility to Cholecalciferol increases response to substance
18628207
D002762 5914 RARA
NR1B1
RAR
retinoic acid receptor, alpha RARA protein mutant form inhibits the reaction [[Cholecalciferol co-treated with TGFB1 protein] results in increased expression of CD14 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
protein 15988048
D002762 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 Cholecalciferol results in increased expression of RB1 protein increases expression
protein 18628207
D002762 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 RAF1 mutant form inhibits the reaction [Cholecalciferol results in increased expression of RB1 protein] decreases reaction
/ increases expression
protein 18628207
D002762 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Cholecalciferol results in decreased phosphorylation of RPS6KB1 protein decreases phosphorylation
protein 18628207
D002762 860 RUNX2
AML3
CBF-alpha-1
CBFA1
CCD
CCD1
CLCD
OSF-2
OSF2
PEA2aA
PEBP2aA
runt-related transcription factor 2 [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 mRNA affects cotreatment
/ increases expression
mRNA 17692823
D002762 6678 SPARC
ON
secreted protein, acidic, cysteine-rich (osteonectin) [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPARC protein affects cotreatment
/ increases expression
protein 17692823
D002762 6696 SPP1
BNSP
BSPI
ETA-1
OPN
secreted phosphoprotein 1 [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPP1 protein affects cotreatment
/ increases expression
protein 17692823
D002762 6901 TAZ
BTHS
CMD3A
EFE
EFE2
G4.5
LVNCX
Taz1
tafazzin [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of TAZ mRNA affects cotreatment
/ increases expression
mRNA 17692823
D002762 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Cholecalciferol co-treated with TGFB1 protein] results in increased expression of CD14 mRNA affects cotreatment
/ increases expression
protein 15988048
D002762 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Cholecalciferol co-treated with TGFB1 protein] results in increased expression of ITGAM mRNA affects cotreatment
/ increases expression
protein 15988048
D002762 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Cholecalciferol co-treated with TGFB1 protein] results in increased expression of ITGAX mRNA affects cotreatment
/ increases expression
protein 15988048
D002762 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 PML protein mutant form inhibits the reaction [[Cholecalciferol co-treated with TGFB1 protein] results in increased expression of CD14 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
protein 15988048
D002762 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 RARA protein mutant form inhibits the reaction [[Cholecalciferol co-treated with TGFB1 protein] results in increased expression of CD14 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
protein 15988048
D002762 4982 TNFRSF11B
OCIF
OPG
TR1
tumor necrosis factor receptor superfamily, member 11b [Chondroitin Sulfates co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA affects cotreatment
/ increases expression
mRNA 17996099
D002762 4982 TNFRSF11B
OCIF
OPG
TR1
tumor necrosis factor receptor superfamily, member 11b [Chondroitin Sulfates co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein affects cotreatment
/ increases expression
protein 17996099
D002762 4982 TNFRSF11B
OCIF
OPG
TR1
tumor necrosis factor receptor superfamily, member 11b [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B mRNA affects cotreatment
/ increases expression
mRNA 17996099
D002762 4982 TNFRSF11B
OCIF
OPG
TR1
tumor necrosis factor receptor superfamily, member 11b [Chondroitin Sulfates co-treated with Glucosamine co-treated with Cholecalciferol] results in increased expression of TNFRSF11B protein affects cotreatment
/ increases expression
protein 17996099
D002762 8600 TNFSF11
CD254
ODF
OPGL
OPTB2
RANKL
TRANCE
hRANKL2
sOdf
tumor necrosis factor (ligand) superfamily, member 11 Cholecalciferol results in increased expression of TNFSF11 mRNA increases expression
mRNA 17996099
D002762 8600 TNFSF11
CD254
ODF
OPGL
OPTB2
RANKL
TRANCE
hRANKL2
sOdf
tumor necrosis factor (ligand) superfamily, member 11 [Chondroitin Sulfates co-treated with Glucosamine] inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 17996099
D002762 8600 TNFSF11
CD254
ODF
OPGL
OPTB2
RANKL
TRANCE
hRANKL2
sOdf
tumor necrosis factor (ligand) superfamily, member 11 Chondroitin Sulfates inhibits the reaction [Cholecalciferol results in increased expression of TNFSF11 mRNA] decreases reaction
/ increases expression
mRNA 17996099
D002762 10628 TXNIP
EST01027
HHCPA78
THIF
VDUP1
thioredoxin interacting protein Cholecalciferol results in increased expression of TXNIP protein increases expression
protein 20713078
D002762 7421 VDR
NR1I1
vitamin D (1,25- dihydroxyvitamin D3) receptor Cholecalciferol promotes the reaction [Fenretinide results in increased expression of VDR] increases expression
/ increases reaction
17024972
D002762 7421 VDR
NR1I1
vitamin D (1,25- dihydroxyvitamin D3) receptor Cholecalciferol results in increased expression of VDR increases expression
17024972
D002762 7431 VIM
CTRCT30
vimentin Cholecalciferol promotes the reaction [Fenretinide results in decreased expression of VIM] decreases expression
/ increases reaction
17024972
D002762 7431 VIM
CTRCT30
vimentin Cholecalciferol results in decreased expression of VIM decreases expression
17024972

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (75)

OMIM preferred title UniProt
#300438 17-beta-hydroxysteroid dehydrogenase x deficiency Q99714
#100100 Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism P20309
#202300 Adrenocortical carcinoma, hereditary; adcc P04637
#103780 Alcohol dependence P08172
P14416
P31645
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#300068 Androgen insensitivity syndrome; ais P10275
#312300 Androgen insensitivity, partial; pais P10275
#614740 Basal cell carcinoma, susceptibility to, 7; bcc7 P04637
#601816 Bilirubin, serum level of, quantitative trait locus 1; biliqtl1 P22309
#602025 Body mass index quantitative trait locus 9; bmiq9 P41968
%606641 Body mass index; bmi P37231
#300615 Brunner syndrome P21397
#609338 Carotid intimal medial thickness 1 P37231
#218800 Crigler-najjar syndrome, type i P22309
P22310
#606785 Crigler-najjar syndrome, type ii P22309
P22310
#162800 Cyclic neutropenia P08246
#612522 Diabetes mellitus, insulin-dependent, 22; iddm22 P51681
#119900 Digital clubbing, isolated congenital P15428
#609535 Drug metabolism, poor, cyp2c19-related P33261
#608902 Drug metabolism, poor, cyp2d6-related P10635
#133239 Esophageal cancer P04637
#615363 Estrogen resistance; estrr P03372
#600274 Frontotemporal dementia; ftd P10636
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#231095 Ghosal hematodiaphyseal dysplasia; ghdd P24557
#143500 Gilbert syndrome P22309
P22310
#137800 Glioma susceptibility 1; glm1 P04626
P37231
#605130 Hairy elbows, short stature, facial dysmorphism, and developmental delay Q03164
#609423 Human immunodeficiency virus type 1, susceptibility to P41597
P51681
#237900 Hyperbilirubinemia, transient familial neonatal; hblrtfn P22309
#145000 Hyperparathyroidism 1; hrpt1 O00255
#259100 Hypertrophic osteoarthropathy, primary, autosomal recessive, 1; phoar1 P15428
#603932 Intervertebral disc disease; idd P14780
#151623 Li-fraumeni syndrome 1; lfs1 P04637
#604367 Lipodystrophy, familial partial, type 3; fpld3 P37231
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P00533
P04626
P04637
#608516 Major depressive disorder; mdd P08172
#300705 Mental retardation, x-linked 17; mrx17 Q99714
%300852 Mental retardation, x-linked 88; mrx88 P50052
#300220 Mental retardation, x-linked, syndromic 10; mrxs10 Q99714
#613073 Metaphyseal anadysplasia 2; mandp2 P14780
#131100 Multiple endocrine neoplasia, type i; men1 O00255
#126200 Multiple sclerosis, susceptibility to; ms P08575
#607948 Mycobacterium tuberculosis, susceptibility to P11473
#159900 Myoclonic dystonia P14416
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#601665 Obesity P32245
P37231
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#259730 Osteopetrosis, autosomal recessive 3; optb3 P00918
#167000 Ovarian cancer P04626
#260500 Papilloma of choroid plexus; cpp P04637
#260540 Parkinson-dementia syndrome P10636
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959
#172700 Pick disease of brain P10636
#607276 Resting heart rate, variation in P08588
#608971 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive P08575
#609620 Short qt syndrome 1; sqt1 Q12809
#313200 Spinal and bulbar muscular atrophy, x-linked 1; smax1 P10275
#253300 Spinal muscular atrophy, type i; sma1 Q16637
#253550 Spinal muscular atrophy, type ii; sma2 Q16637
#253400 Spinal muscular atrophy, type iii; sma3 Q16637
#271150 Spinal muscular atrophy, type iv; sma4 Q16637
#607250 Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy; scan1 Q9NUW8
#275355 Squamous cell carcinoma, head and neck; hnscc P04637
#601104 Supranuclear palsy, progressive, 1; psnp1 P10636
#188570 Thyroid hormone resistance, generalized, autosomal dominant; grth P10828
#274300 Thyroid hormone resistance, generalized, autosomal recessive; grth P10828
#145650 Thyroid hormone resistance, selective pituitary; prth P10828
#190300 Tremor, hereditary essential, 1; etm1 P35462
#277440 Vitamin d-dependent rickets, type 2a; vddr2a P11473
#610379 West nile virus, susceptibility to P51681
#112100 Yt blood group antigen P22303

KEGG DISEASE (80)

KEGG disease name UniProt
H00033 Adrenal carcinoma O00255 (related)
P04637 (related)
H00034 Carcinoid O00255 (related)
H00045 Malignant islet cell carcinoma O00255 (related)
H00246 Primary hyperparathyroidism O00255 (related)
H01102 Pituitary adenomas O00255 (related)
H00016 Oral cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00017 Esophageal cancer P00533 (related)
P04637 (related)
P04637 (marker)
P35354 (related)
H00018 Gastric cancer P00533 (related)
P04626 (related)
P04637 (related)
H00022 Bladder cancer P00533 (related)
P04626 (related)
P04637 (related)
H00028 Choriocarcinoma P00533 (related)
P03956 (related)
P04626 (related)
P04637 (related)
H00030 Cervical cancer P00533 (related)
P04626 (related)
H00042 Glioma P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00055 Laryngeal cancer P00533 (related)
P00533 (marker)
P04637 (related)
P04637 (marker)
H00241 Combined proximal and distal renal tubular acidosis (RTA type 3) P00918 (related)
H00436 Osteopetrosis P00918 (related)
H00026 Endometrial Cancer P03372 (marker)
P04626 (related)
P04637 (related)
Q92731 (marker)
H00599 46,XX disorders of sex development (Disorders related to androgen excess) P04150 (related)
H00019 Pancreatic cancer P04626 (related)
P04637 (related)
P04637 (marker)
H00027 Ovarian cancer P04626 (related)
P04637 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
P04637 (related)
H00046 Cholangiocarcinoma P04626 (related)
P04637 (related)
P35354 (related)
H00004 Chronic myeloid leukemia (CML) P04637 (related)
H00005 Chronic lymphocytic leukemia (CLL) P04637 (related)
H00006 Hairy-cell leukemia P04637 (related)
H00008 Burkitt lymphoma P04637 (related)
H00009 Adult T-cell leukemia P04637 (related)
H00010 Multiple myeloma P04637 (related)
H00013 Small cell lung cancer P04637 (related)
H00014 Non-small cell lung cancer P04637 (related)
H00015 Malignant pleural mesothelioma P04637 (related)
H00020 Colorectal cancer P04637 (related)
P04637 (marker)
H00025 Penile cancer P04637 (related)
P04637 (marker)
P14780 (related)
P35354 (related)
H00029 Vulvar cancer P04637 (related)
H00032 Thyroid cancer P04637 (related)
P37231 (related)
H00036 Osteosarcoma P04637 (related)
P08684 (marker)
H00038 Malignant melanoma P04637 (related)
H00039 Basal cell carcinoma P04637 (related)
Q99835 (related)
H00040 Squamous cell carcinoma P04637 (related)
H00041 Kaposi's sarcoma P04637 (related)
H00044 Cancer of the anal canal P04637 (related)
H00047 Gallbladder cancer P04637 (related)
H00048 Hepatocellular carcinoma P04637 (related)
H00881 Li-Fraumeni syndrome P04637 (related)
H01007 Choroid plexus papilloma P04637 (related)
H00021 Renal cell carcinoma P04637 (marker)
H00093 Combined immunodeficiencies (CIDs) P06239 (related)
H00079 Asthma P07550 (related)
H00100 Neutropenic disorders P08246 (related)
H00091 T-B+Severe combined immunodeficiencies (SCIDs) P08575 (related)
H00024 Prostate cancer P10275 (related)
H00062 Spinal and bulbar muscular atrophy (SBMA) P10275 (related)
H00608 46,XY disorders of sex development (Disorders in androgen synthesis or action) P10275 (related)
H00609 46,XY disorders of sex development (Other) P10275 (related)
H00058 Amyotrophic lateral sclerosis (ALS) P10636 (related)
H00077 Progressive supranuclear palsy (PSP) P10636 (related)
H00078 Frontotemporal lobar degeneration (FTLD) P10636 (related)
H00249 Thyroid hormone resistance syndrome P10828 (related)
H00342 Tuberculosis P11473 (related)
H00784 Localized autosomal recessive hypotrichosis P11473 (related)
H01143 Vitamin D-dependent rickets P11473 (related)
H01205 Coumarin resistance P11712 (related)
H00479 Metaphyseal dysplasias P14780 (related)
H00457 Primary hypertrophic osteoarthropathy (PHO) P15428 (related)
H01246 Isolated congenital nail clubbing (ICNC) P15428 (related)
H00548 Brunner syndrome P21397 (related)
H00208 Hyperbilirubinemia P22309 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)
H00490 Diaphyseal dysplasia with anemia (Ghosal) P24557 (related)
H01171 Poor drug metabolism (PM) P33261 (related)
H00409 Type II diabetes mellitus P37231 (related)
H00420 Familial partial lipodystrophy (FPL) P37231 (related)
H00480 Non-syndromic X-linked mental retardation P50052 (related)
Q99714 (related)
H00001 Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) Q03164 (related)
Q03164 (marker)
H00002 Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia) Q03164 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)
H00455 Spinal muscular atrophy (SMA) Q16637 (related)
Q16637 (related)
H00658 Syndromic X-linked mental retardation Q99714 (related)
H00925 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency Q99714 (related)
H00063 Spinocerebellar ataxia (SCA) Q9NUW8 (related)

Diseases related to CTD interactions

35 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D058186 D002762 Acute Kidney Injury marker/mechanism
3380067
6330660
19856155
D000307 D002762 Adrenal Gland Diseases marker/mechanism
10496673
D001018 D002762 Aortic Diseases marker/mechanism
12803500
D001161 D002762 Arteriosclerosis marker/mechanism
1648535
D050197 D002762 Atherosclerosis marker/mechanism
223374
2989135
19931584
D001327 D002762 Autoimmune Diseases therapeutic
16142846
D002114 D002762 Calcinosis marker/mechanism
4340673
12803500
16378124
D006332 D002762 Cardiomegaly marker/mechanism
2154115
D015362 D002762 Child Nutrition Disorders marker/mechanism
21048240
D003324 D002762 Coronary Artery Disease marker/mechanism
1648535
2989135
D004342 D002762 Drug Hypersensitivity marker/mechanism
2995910
D064420 D002762 Drug-Related Side Effects and Adverse Reactions marker/mechanism
3380067
D005767 D002762 Gastrointestinal Diseases marker/mechanism
15460982
D006130 D002762 Growth Disorders marker/mechanism
14968361
D006934 D002762 Hypercalcemia marker/mechanism
232048
1322674
2995910
3380067
4340673
4368776
6087399
6286738
6299054
7250652
7604500
7657155
8711172
10490077
11332696
14968361
19856155
20427501
21048240
D053565 D002762 Hypercalciuria marker/mechanism
19185560
D054559 D002762 Hyperphosphatemia marker/mechanism
6286738
10490077
21048240
D006965 D002762 Hyperplasia marker/mechanism
10496673
D006973 D002762 Hypertension marker/mechanism
15460982
D006996 D002762 Hypocalcemia therapeutic
80633
D020347 D002762 Lithiasis marker/mechanism
21670126
D008325 D002762 Mammary Neoplasms, Experimental therapeutic
21843606
D009120 D002762 Muscle Cramp therapeutic
1657745
D009123 D002762 Muscle Hypotonia marker/mechanism
14968361
D010018 D002762 Osteomalacia therapeutic
1013714
D010673 D002762 Pheochromocytoma marker/mechanism
10496673
D017285 D002762 Polymyositis marker/mechanism
20427501
D011471 D002762 Prostatic Neoplasms therapeutic
17024972
D051437 D002762 Renal Insufficiency marker/mechanism
15460982
D012279 D002762 Rickets therapeutic
21048240
D013971 D002762 THYROTOXICOSIS therapeutic
1657745
D061205 D002762 Vascular Calcification marker/mechanism
23104429
D014652 D002762 Vascular Diseases marker/mechanism
16378124
19910445
D014808 D002762 Vitamin D Deficiency marker/mechanism
therapeutic
1657745
2154115
20427501
21329450
D015431 D002762 Weight Loss marker/mechanism
10490077